Ilona Sviezhentseva

Ilona Sviezhentseva

Ph.D.

Languages for professional communication:

Ukrainian, English, Polish

Description of the field of scientific research:

Ilona studies the molecular biology of malignant tumor development, personalized medicine, cancer stem cell, and translational biology. She is interested in the sustainability of innovation systems. She pays special attention to the study of innovation systems in Ukraine and the study of the science of science in Ukraine.

List of duties:

Ilona is a postdoctoral fellow in the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, part of the Harvard University School of Medicine (Boston, USA). He is engaged in the study of molecular mechanisms of acute myeloid leukemia.

Professional experience:

From 2009 to 2012, Ilona was a laboratory assistant at the Center for Molecular and Cellular Research at the National University of Kyiv-Mohyla Academy. From 2012 to 2015, she was a Ph.D. student at the Department of Laboratory Diagnostics of Biological Systems at the same university, and the following year she held a postdoctoral position at the Department of Immunology at Nicolaus Copernicus University.

In 2018-2020, Ilona worked as a medical interpreter at the University of Western Ontario clinics. From 2021 to 2022, she held the position of science and medical journalist at the Suspilne media platform, and from 2022 to the present, she has been a postdoc at the Dana-Farber Cancer Institute, Harvard University Medical School (Boston, USA).

In addition, in 2020-2021, Ilona was a scientific literature reviewer for the Canadian Leukemia and Lymphoma Society.

Keywords:

  • Science popularization

  • Book writing

  • Biology

  • Science communications

  • Medicine

Basic scientific publications:

  • Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy

    Sviezhentseva I.O., Perekhrestenko T.P., Bilko D.I., Gordienko A.I., Diachenko M.V., Dyagil I.S., Experimental Oncology. 2015. 37, №1. 2015

    Role: Author

  • Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors

    l. Sviezhentseva, T. Perekhrestenko, D. BilkoD. Bilko, N. Bilko Experimental Oncology. 2014. 36, №2. 2014

    Role: Author

Contact a scientist

Fill out this form to contact the scientist directly